Gemphire reports Phase IIb data of gemcabene for hypercholesterolemia

Gemphire Therapeutics Inc. (NASDAQ:GEMP) reported top-line data from the Phase IIb ROYAL-1 trial in 105 patients with hypercholesterolemia showing that once-daily 600 mg oral gemcabene (CI-1027) met the primary endpoint of reducing mean LDL-C from

Read the full 357 word article

How to gain access

Continue reading with a
two-week free trial.